INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH (ISPOR) EXPANDS LEADERSHIP TEAM

Published Oct 28, 2015

BETSY LANE JOINS ISPOR AS CHIEF MARKETING & COMMUNICATIONS OFFICER 

Princeton, NJ—October 28, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced that Betsy Lane has been appointed director and chief marketing and communications officer for the organization. Lane will lead ISPOR’s global marketing and communications efforts to help further advance the organization’s mission to promote health economics and outcomes research excellence to improve decision making for health globally. Lane has over 25 years’ experience in the life sciences industry. Prior to joining ISPOR, she served as senior vice president, marketing and communications at Publicis Touchpoint Solutions. Previously, she worked for several medical advertising agencies leading agency teams primarily focused on specialty product launches in the oncology, endocrinology, CNS, and dermatology therapeutic areas. Lane began her career working as a pharmaceutical sales representative. While at Johnson & Johnson, she served in a variety of increasingly significant roles, including divisional sales manager and product manager. “We are excited to have Betsy join the ISPOR team,” stated Nancy Berg, chief executive officer and executive director. “Our organization has grown tremendously over the years and we believe that Betsy’s experience will help us to further our mission by more effectively communicating the great work that ISPOR does day in and day out.”

###

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Europe 2025 Plenaries and Speakers Announced

Oct 13, 2025

ISPOR announced details for its ISPOR Europe 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×